http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 15 Oct 2026 05:33:38 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Bright+Minds+Biosciences+Inc.+%28DRUG%29+at+Outperform/27188675.html <p>Wolfe Research initiates coverage on Bright Minds Biosciences Inc. (NASDAQ: DRUG) with a Outperform rating and a price target of $150.00.</p><p>For an analyst ratings summary and ratings history on Bright Minds Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=DRUG">click here</a>. For more ratings news on Bright Minds Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=DRUG&amp;type=analyst">click here</a>.</p><p>Shares of Bright Minds Biosciences Inc. closed at $50.71 yesterday.</p> http://www.streetinsider.com/New+Coverage/Wolfe+Research+Starts+Bright+Minds+Biosciences+Inc.+%28DRUG%29+at+Outperform/27188675.html Thu, 15 Oct 2026 05:33:38 -0400 DRUG http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Bright+Minds+Biosciences+Inc.+%28DRUG%29+at+Outperform/27188675.html <p>Wolfe Research initiates coverage on Bright Minds Biosciences Inc. (NASDAQ: DRUG) with a Outperform rating and a price target of $150.00.</p><p>For an analyst ratings summary and ratings history on Bright Minds Biosciences Inc. <a href="http://www.streetinsider.com/rating_history.php?q=DRUG">click here</a>. For more ratings news on Bright Minds Biosciences Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=DRUG&amp;type=analyst">click here</a>.</p><p>Shares of Bright Minds Biosciences Inc. closed at $50.71 yesterday.</p> http://www.streetinsider.com/Hot+New+Coverage/Wolfe+Research+Starts+Bright+Minds+Biosciences+Inc.+%28DRUG%29+at+Outperform/27188675.html Thu, 15 Oct 2026 05:33:38 -0400 DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/27143514.html si-local-file:///var/storage/secattach/20261002/27143514.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/27143514.html Fri, 02 Oct 2026 17:14:00 -0400 DRUG DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/27143514.html si-local-file:///var/storage/secattach/20261002/27143514.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Mar+31/27143514.html Fri, 02 Oct 2026 17:14:00 -0400 DRUG DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Sep+30/27130820.html si-local-file:///var/storage/secattach/20261001/27130820.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Sep+30/27130820.html Thu, 01 Oct 2026 06:04:00 -0400 DRUG DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Sep+30/27130820.html si-local-file:///var/storage/secattach/20261001/27130820.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Sep+30/27130820.html Thu, 01 Oct 2026 06:04:00 -0400 DRUG DRUG http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Participate+in+the+2026+FPWR+Research+Symposium+and+PWS+Family+Conference/27129664.html <p align="justify">NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- <strong>Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)</strong> (“<strong>Bright Minds</strong>” or the “<strong>Company</strong>”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.</p> <p align="justify">The FPWR meeting brings together families, caregivers, clinicians, researchers, and industry to share the latest in http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Participate+in+the+2026+FPWR+Research+Symposium+and+PWS+Family+Conference/27129664.html Wed, 30 Sep 2026 17:30:00 -0400 DRUG http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Participate+in+the+2026+FPWR+Research+Symposium+and+PWS+Family+Conference/27129664.html <p align="justify">NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- <strong>Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG)</strong> (“<strong>Bright Minds</strong>” or the “<strong>Company</strong>”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.</p> <p align="justify">The FPWR meeting brings together families, caregivers, clinicians, researchers, and industry to share the latest in http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Participate+in+the+2026+FPWR+Research+Symposium+and+PWS+Family+Conference/27129664.html Wed, 30 Sep 2026 17:30:00 -0400 DRUG http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/27030222.html <p>NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:8%; width:8%; min-width:8%;;text-align: left ; vertical-align: middle; vertical-align: top ; "> </td><td style="max-width:10%; width:10%; min-width:10%;;text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>EVENT:</strong></td><td style="max-width:82%; width:82%; min-width:82%;;text-align: left ; vertical-align: middle; vertical-align: top http://www.streetinsider.com/Press+Releases/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/27030222.html Fri, 04 Sep 2026 16:30:00 -0400 DRUG http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/27030222.html <p>NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tr><td style="max-width:8%; width:8%; min-width:8%;;text-align: left ; vertical-align: middle; vertical-align: top ; "> </td><td style="max-width:10%; width:10%; min-width:10%;;text-align: left ; vertical-align: middle; vertical-align: top ; "><strong>EVENT:</strong></td><td style="max-width:82%; width:82%; min-width:82%;;text-align: left ; vertical-align: middle; vertical-align: top http://www.streetinsider.com/Globe+Newswire/Bright+Minds+Biosciences+to+Present+at+Upcoming+Conferences/27030222.html Fri, 04 Sep 2026 16:30:00 -0400 DRUG http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Bright+Minds+Biosciences+Inc.+%28DRUG%29/26952553.html <p>H.C. Wainwright analyst Pat Trucchio reiterated a Buy rating and $145.00 price target on Bright Minds Biosciences Inc. (NASDAQ: DRUG).</p><p>The analyst commented: "On August 17, Bright Minds filed its F3Q26 results (ending June '26). Future registrational trials evaluating BMB-101 in absence seizures and developmental and epileptic encephalopathies (DEEs) remain characterized as preparatory activities that are ongoing; we continue to look for the end-of-Phase 2 (EOP2) interaction with the FDA, endpoint and dose alignment, and initiation the registrational trials in 2H26 as the next de-risking steps. Separately, on July 20, Lundbeck (HLUN-B.CO; not rated) announced that bexicaserin, a highly selective 5-HT2C http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Bright+Minds+Biosciences+Inc.+%28DRUG%29/26952553.html Thu, 20 Aug 2026 06:59:01 -0400 DRUG http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jun+30/26934173.html si-local-file:///var/storage/secattach/20260817/26934173.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jun+30/26934173.html Mon, 17 Aug 2026 06:03:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jun+30/26934173.html si-local-file:///var/storage/secattach/20260817/26934173.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++BRIGHT+MINDS+BIOSCIENCES++For%3A+Jun+30/26934173.html Mon, 17 Aug 2026 06:03:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26928715.html si-local-file:///var/storage/secattach/20260814/26928715.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26928715.html Fri, 14 Aug 2026 14:02:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26928715.html si-local-file:///var/storage/secattach/20260814/26928715.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Cormorant+Asset+Management%2C+LP/26928715.html Fri, 14 Aug 2026 14:02:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BRIGHT+MINDS+BIOSCIENCES+++++++++++++/26915657.html si-local-file:///var/storage/secattach/20260813/26915657.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BRIGHT+MINDS+BIOSCIENCES+++++++++++++/26915657.html Thu, 13 Aug 2026 06:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BRIGHT+MINDS+BIOSCIENCES+++++++++++++/26915657.html si-local-file:///var/storage/secattach/20260813/26915657.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++BRIGHT+MINDS+BIOSCIENCES+++++++++++++/26915657.html Thu, 13 Aug 2026 06:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911237.html si-local-file:///var/storage/secattach/20260812/26911237.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911237.html Wed, 12 Aug 2026 12:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911237.html si-local-file:///var/storage/secattach/20260812/26911237.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++BRIGHT+MINDS+BIOSCIENCES+++++++++++++++Filed+by%3A+Adage+Capital+Management%2C+L.P./26911237.html Wed, 12 Aug 2026 12:05:00 -0400 DRUG O.53098441 http://www.streetinsider.com/Board+Changes/Vistagen+names+neuroscience+veteran+Douglas+Williamson+to+its+board/26847241.html <p>Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced the appointment of Douglas J. Williamson, MD, to its board of directors, according to a press release.</p> <p>Dr. Williamson is currently a CNS drug development consultant and founder of Destiny Biopharm Consulting. He most recently served as chief medical officer of QurAlis Corporation. Before that, he was executive vice president and head of research and development at Acadia Pharmaceuticals, where he led the company's neuroscience pipeline strategy.</p> <p>Earlier in his career, Dr. Williamson held the role of chief medical officer at Avadel Pharmaceuticals and senior leadership positions at H. Lundbeck A/S, including senior http://www.streetinsider.com/Board+Changes/Vistagen+names+neuroscience+veteran+Douglas+Williamson+to+its+board/26847241.html Fri, 31 Jul 2026 08:30:10 -0400 DRUG VTGN http://www.streetinsider.com/Board+Changes/Vistagen+names+neuroscience+veteran+Douglas+Williamson+to+its+board/26847241.html <p>Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company, announced the appointment of Douglas J. Williamson, MD, to its board of directors, according to a press release.</p> <p>Dr. Williamson is currently a CNS drug development consultant and founder of Destiny Biopharm Consulting. He most recently served as chief medical officer of QurAlis Corporation. Before that, he was executive vice president and head of research and development at Acadia Pharmaceuticals, where he led the company's neuroscience pipeline strategy.</p> <p>Earlier in his career, Dr. Williamson held the role of chief medical officer at Avadel Pharmaceuticals and senior leadership positions at H. Lundbeck A/S, including senior http://www.streetinsider.com/Board+Changes/Vistagen+names+neuroscience+veteran+Douglas+Williamson+to+its+board/26847241.html Fri, 31 Jul 2026 08:30:10 -0400 DRUG VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html <p><strong>Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy</strong></p><p>SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kZdqRZtcpnpaH3Jq0JPAXyi6WlV-kyKUyjEyUZ6U5rrI726iRVAbzPtX_ER7Igd-6lgjlA1p75dxrglzZPC0bA==" rel="nofollow" target="_blank">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Board of Directors (“Board”). Dr. Williamson brings extensive experience leading neuroscience drug development programs from early clinical research through regulatory approval and commercialization.</p> <p>“We are pleased to welcome Dr. Williamson http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html Fri, 31 Jul 2026 08:30:00 -0400 DRUG VTGN VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html <p><strong>Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy</strong></p><p>SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kZdqRZtcpnpaH3Jq0JPAXyi6WlV-kyKUyjEyUZ6U5rrI726iRVAbzPtX_ER7Igd-6lgjlA1p75dxrglzZPC0bA==" rel="nofollow" target="_blank">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Board of Directors (“Board”). Dr. Williamson brings extensive experience leading neuroscience drug development programs from early clinical research through regulatory approval and commercialization.</p> <p>“We are pleased to welcome Dr. Williamson http://www.streetinsider.com/Globe+Newswire/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html Fri, 31 Jul 2026 08:30:00 -0400 DRUG VTGN VTGN http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html <p><strong>Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy</strong></p><p>SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kZdqRZtcpnpaH3Jq0JPAXyi6WlV-kyKUyjEyUZ6U5rrI726iRVAbzPtX_ER7Igd-6lgjlA1p75dxrglzZPC0bA==" rel="nofollow" target="_blank">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Board of Directors (“Board”). Dr. Williamson brings extensive experience leading neuroscience drug development programs from early clinical research through regulatory approval and commercialization.</p> <p>“We are pleased to welcome Dr. Williamson http://www.streetinsider.com/Press+Releases/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html Fri, 31 Jul 2026 08:30:00 -0400 DRUG VTGN VTGN http://www.streetinsider.com/Globe+Newswire/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html <p><strong>Dr. Williamson brings nearly three decades of leadership experience in neuroscience drug development, clinical research, and regulatory strategy</strong></p><p>SOUTH SAN FRANCISCO, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=kZdqRZtcpnpaH3Jq0JPAXyi6WlV-kyKUyjEyUZ6U5rrI726iRVAbzPtX_ER7Igd-6lgjlA1p75dxrglzZPC0bA==" rel="nofollow" target="_blank">Vistagen</a> (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Douglas J. Williamson, MD, to its Board of Directors (“Board”). Dr. Williamson brings extensive experience leading neuroscience drug development programs from early clinical research through regulatory approval and commercialization.</p> <p>“We are pleased to welcome Dr. Williamson http://www.streetinsider.com/Globe+Newswire/Vistagen+Appoints+Douglas+J.+Williamson+to+its+Board+of+Directors/26847218.html Fri, 31 Jul 2026 08:30:00 -0400 DRUG VTGN VTGN